Institut Bergonié and Seven and Eight Biopharmaceuticals Inc. Announce the First Patient Treated in the AGADIR Study of BDB001 in Combination with Atezolizumab and Immunogenic Radiotherapy in Solid Tumors

On May 18, 2021 Institut Bergonié, a cancer center based in Bordeaux, and Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company specializing in immuno-oncology, reported the treatment of the first patient in their collaboration to study BDB001 (Press release, Seven and Eight Biopharmaceuticals, MAY 18, 2021, View Source [SID1234580211]). Institut Bergonié is the sponsor of the AGADIR Phase II protocol, "Atezolizumab combined with BDB001 and Immunogenic Radiotherapy in patients with advanced solid tumors" (NCT03915678), which will enroll patients with difficult-to-treat solid tumors across 10 clinical centers in France. The study is funded in a public-private partnership by a grant from the French National Cancer Institute (Institut National du Cancer, INCa) and the Fondation ARC (La Fondation ARC pour la recherche sur le cancer) (INCa-ARC_13579) and performed in collaboration with Roche, who will supply atezolizumab. BDB001 is a first-in-class Toll-like receptor 7/8 (TLR7/8) agonist, which is delivered intravenously, allowing for broader treatment of solid tumors compared to intratumoral TLR agonists in development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to begin this clinical study with BDB001. Our collaboration with Seven and Eight Biopharma allows us to explore a new and potentially valuable treatment option to our patients," declared Professor Antoine Italiano, Head of Early Phase Trials Unit, Institut Bergonié.

"This partnership with Institut Bergonié is a milestone in our development program for BDB001. The clinical trial expertise provided by Institut Bergonié and their collaborators will help us better understand the potential role for BDB001 as an immuno-oncology backbone in combination with checkpoint inhibitors and radiotherapy in the treatment of solid tumors," says Dr. Robert Andtbacka, Chief Medical Officer at Seven and Eight Biopharma Inc.